For the year ending 2025-12-31, CRSP had $49,302K increase in cash & cash equivalents over the period. -$345,928K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -581,599 |
| Depreciation and amortization | 19,479 |
| Stock-based compensation expense | 72,499 |
| Other non-cash items, net | 23,528 |
| Acquired in-process research and development | 96,253 |
| Accounts receivable | -25,000 |
| Prepaid expenses and other assets | -3,337 |
| Accounts payable and accrued expenses | 44,894 |
| Deferred revenue | -397 |
| Operating lease assets and liabilities | -5,210 |
| Other liabilities, net | 4,258 |
| Net cash used in operating activities | -345,014 |
| Purchase of property, plant and equipment | 914 |
| Purchase of in-process research and development | 25,000 |
| Investment in equity securities | 9,700 |
| Sale of equity securities | 702 |
| Purchases of marketable debt securities | 1,008,170 |
| Maturities of marketable debt securities | 1,011,277 |
| Net cash used in (provided by) investing activities | -31,805 |
| Proceeds from issuance of common shares, net of issuance costs | 398,090 |
| Proceeds from exercise of options and espp contributions, net of issuance costs | 27,936 |
| Net cash provided by financing activities | 426,026 |
| Effect of exchange rate changes on cash | 95 |
| Increase (decrease) in cash | 49,302 |
| Cash and cash equivalents at beginning of period | 309,776 |
| Cash and cash equivalents at end of period | 359,078 |
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)